Critical Illness After Hematopoietic Cell Transplantation

N/ANot Yet RecruitingNCT07328724

Peking University People's Hospital4,000 enrolled

Overview

This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation. Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation at the participating medical centers will be enrolled in this study. The clinical characteristics, laboratory profiles, managements, and clinical outcomes will be prospectively collected.

Study Type

OBSERVATIONAL

Enrollment

4,000

Conditions

Critical Illness Ventilated Patients Hematopoetic Stem Cell Transplantation Transplant Complication

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who underwent hematopoietic cell transplantation at any of the participating medical centers. * Patients who are admitted to ICU for the management of critical illness following hematopoietic cell transplantation. Exclusion Criteria: * Admitted to ICU for a reason other than critical illness (e.g., routine postoperative monitoring) and discharged within 2 days of ICU admission. * Unavailable in-ICU clinical outcomes or absent key baseline characteristics. * Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.

Locations (6)

Peking University People's Hospital

Beijing, China

Xinqiao hospital of the third military medical university

Chongqing, China

First Affiliated Hospital of Zhejiang University

Hangzhou, China

First Affiliated Hospital of Harbin Medical University

Harbin, China

Hematology Hospital of Chinese Academy of Medical Sciences

Tianjin, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China

Outcomes

Primary Outcomes

Overall survival

Overall survival after admission to the intensive care unit.

Time frame: Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge.

Secondary Outcomes

Non-relapse mortality

Non-relapse mortality after ICU admission.

Time frame: Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge.

Relapse

Disease relapse or progression at or after ICU admission.

Time frame: At ICU admission and within 1 year of ICU discharge.

Transplant complication

Hematopoietic-cell-transplantation-associated complications at or after ICU admission.

Time frame: At ICU admission and within 1 year of ICU discharge.

Organ failure

Organ failure occurring at or after ICU admission.

Time frame: At ICU admission and within 1 year of ICU discharge.

Organ support therapy

The use of organ support therapy at or after ICU admission.

Time frame: At ICU admission and within 1 year after ICU discharge.

Long-term survival data

Overall survival, non-relapse mortality, and transplant-related mortality during long-term follow-up after ICU discharge.

Time frame: Up to 5 years after ICU discharge.

Critical Illness After Hematopoietic Cell Transplantation

Overview

Conditions

Eligibility

Locations (6)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts